Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

Page standards status: Informative
.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 PublicationRecord Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Changes
... 15 Artifacts Summary
.... 15.1 AbsenceOfExposureDefinition
.... 15.2 Adaptation
.... 15.3 AdverseEventsReport
.... 15.4 BaselineMeasureEvidence
.... 15.5 BaselineMeasureReport
.... 15.6 BaselineVariablesList
.... 15.7 BookCitation
.... 15.8 BookPartCitation
.... 15.9 CertaintyOfEvidence
.... 15.10 Classification
.... 15.11 CohortDefinition
.... 15.12 Comment
.... 15.13 ComparativeBaselineMeasureEvidence
.... 15.14 ComparativeEvidence
.... 15.15 ComparativeEvidenceReport
.... 15.16 ComparativeEvidenceReportExpanded
.... 15.17 ComparativeEvidenceReportSubject
.... 15.18 ComparativeEvidenceSynthesisReport
.... 15.19 ComparativeParticipantFlowEvidence
.... 15.20 ComparatorGroup
.... 15.21 ComparatorOnlyEvidence
.... 15.22 Comparison
.... 15.23 CompositeRating
.... 15.24 ConceptualCohortDefinition
.... 15.25 ConceptualComparatorDefinition
.... 15.26 ConceptualExposureDefinition
.... 15.27 DatabaseCitation
.... 15.28 DatabaseEntryCitation
.... 15.29 DatasetCitation
.... 15.30 DateAsRating
.... 15.31 DichotomousIntendedOutcome
.... 15.32 EndpointAnalysisPlan
.... 15.33 EvidenceAssessment
.... 15.34 EvidenceList
.... 15.35 EvidenceReport
.... 15.36 EvidenceReportPackage
.... 15.37 EvidenceReportSubject
.... 15.38 EvidenceSynthesisEvidence
.... 15.39 ExposureGroup
.... 15.40 GroupAssignment
.... 15.41 GroupR6
.... 15.42 Guideline
.... 15.43 InterventionOnlyEvidence
.... 15.44 JournalArticleCitation
.... 15.45 M11ReportContainer
.... 15.46 M11ReportSection01
.... 15.47 M11ReportSection02
.... 15.48 M11ReportSection03
.... 15.49 M11ReportSection04
.... 15.50 M11ReportSection05
.... 15.51 M11ReportSection06
.... 15.52 M11ReportSection07
.... 15.53 M11ReportSection08
.... 15.54 M11ReportSection09
.... 15.55 M11ReportSection10
.... 15.56 M11ReportSection11
.... 15.57 M11ReportSection12
.... 15.58 M11ReportSection13
.... 15.59 M11ReportSection14
.... 15.60 MetaanalysisEligibilityCriteria
.... 15.61 MetaanalysisOutcomeDefinition
.... 15.62 MetaanalysisStudyGroup
.... 15.63 NetEffectContribution
.... 15.64 NetEffectContributionList
.... 15.65 NetEffectContributions
.... 15.66 NetEffectEstimate
.... 15.67 NonComparativeEvidence
.... 15.68 OutcomeDefinition
.... 15.69 OutcomeImportance
.... 15.70 OutcomeList
.... 15.71 OutcomeMeasureReport
.... 15.72 OutcomeVariablesList
.... 15.73 ParticipantFlowEvidence
.... 15.74 ParticipantFlowEvidenceVariable
.... 15.75 ParticipantFlowReasonEvidenceVariable
.... 15.76 ParticipantFlowReport
.... 15.77 ParticipantFlowVariablesList
.... 15.78 PICOSpecification
.... 15.79 PICOTaggedComposition
.... 15.80 PICOTaggedEvidence
.... 15.81 PreprintCitation
.... 15.82 Rating
.... 15.83 Recommendation
.... 15.84 RecommendationAction
.... 15.85 RecommendationEligibilityCriteria
.... 15.86 RecommendationJustification
.... 15.87 RecommendationPlan
.... 15.88 RecommendationRating
.... 15.89 ResearchStudyDataDictionary
.... 15.90 ResearchStudySite
.... 15.91 ResearchStudySupport
.... 15.92 RiskOfBias
.... 15.93 SearchResults
.... 15.94 SearchStrategy
.... 15.95 SingleStudyEvidence
.... 15.96 SoaPlanDefinition
.... 15.97 SoftwareCitation
.... 15.98 StatisticModel
.... 15.99 StudyComponent
.... 15.100 StudyDesign
.... 15.101 StudyEligibilityCriteria
.... 15.102 StudyGroup
.... 15.103 StudyRegistryRecord
.... 15.104 SummaryOfFindings
.... 15.105 SummaryOfNetEffect
.... 15.106 SystematicReview
.... 15.107 SystematicReviewEligibilityCriteria
.... 15.108 SystematicReviewExcludedStudies
.... 15.109 SystematicReviewIncludedStudies
.... 15.110 VariableDefinition
.... 15.111 WebPageCitation
.... 15.112 ArtifactAssessmentCompared
.... 15.113 ArtifactAssessmentDateAsRating
.... 15.114 ArtifactPublicationStatus
.... 15.115 ArtifactRecorder
.... 15.116 CharacteristicTiming
.... 15.117 CiteAs
.... 15.118 GuidelineRegistration
.... 15.119 NumberAnalyzed
.... 15.120 RelatesToClassifier
.... 15.121 RelatesToWithQuotation
.... 15.122 RelativeOutcomeImportance
.... 15.123 RelevantForAutomatedMatching
.... 15.124 ResearchStudyExcludedStudy
.... 15.125 ResearchStudyIncludedStudy
.... 15.126 ResearchStudyIsLowInterventionTrial
.... 15.127 ResearchStudyIsRareDisease
.... 15.128 ResearchStudyNumberOfStudiesIdentified
.... 15.129 ResearchStudyNumberOfStudiesIncluded
.... 15.130 ResearchStudySaeReportingMethod
.... 15.131 ResearchStudySearchStrategy
.... 15.132 ResearchStudySponsorConfidentialityStatement
.... 15.133 ResearchStudyStudyAmendment
.... 15.134 ResearchStudySystematicReviewEligibilityCriteria
.... 15.135 StatisticModelExpression
.... 15.136 StatisticModelIncludeIf
.... 15.137 Desirability Codes Value Set
.... 15.138 EBMonFHIR Profile Name Value Set
.... 15.139 Evidence Rating System Classifier Codes Value Set
.... 15.140 PICO Classification Value Set
.... 15.141 Recommendation Justification Classifier Codes Value Set
.... 15.142 Research Study Document Types Value Set
.... 15.143 ResearchStudy Classifier Value Set
.... 15.144 Search Strategy Characteristic Value Set
.... 15.145 Desirability Code System
.... 15.146 EBMonFHIR Profile Name Code System
.... 15.147 Evidence Rating System Classifier Code System
.... 15.148 Research Study Document Types Code System
.... 15.149 Search Strategy Characteristic Code System
.... 15.150 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 15.151 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.152 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 15.153 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 15.154 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 15.155 179899
.... 15.156 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 15.157 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 15.158 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 15.159 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 15.160 19967827 Wonder woman was Argentine and her real name was Evita.
.... 15.161 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 15.162 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 15.163 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 15.164 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 15.165 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 15.166 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 15.167 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 15.168 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 15.169 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 15.170 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 15.171 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 15.172 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 15.173 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 15.174 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 15.175 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 15.176 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 15.177 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 15.178 27979893 6. Glycemic Targets.
.... 15.179 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 15.180 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 15.181 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 15.182 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 15.183 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 15.184 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 15.185 30467172 Finding my inner Wonder Woman.
.... 15.186 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 15.187 33008778 Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis.
.... 15.188 34871555 What Can Wonder Woman Teach Radiologists?
.... 15.189 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 15.190 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 15.191 367832
.... 15.192 367833
.... 15.193 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 15.194 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.
.... 15.195 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 15.196 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
.... 15.197 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.198 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.199 Add-on Amlodipine at 6 weeks
.... 15.200 Adults hospitalized with COVID-19 pneumonia
.... 15.201 Adults with diabetes mellitus type 2
.... 15.202 Adults with type 2 diabetes and CVD and CKD
.... 15.203 Adults with type 2 diabetes and established CVD (but no CKD)
.... 15.204 Adverse event free and hypertension control
.... 15.205 Adverse event free and hypertension control at 12 weeks
.... 15.206 Adverse Events Report for NCT03421379
.... 15.207 Adverse Events Report for NCT03640312
.... 15.208 Age
.... 15.209 Age with comparator
.... 15.210 Age with intervention
.... 15.211 Aircraft Type
.... 15.212 Aircraft Type with comparator
.... 15.213 Aircraft Type with intervention
.... 15.214 Altitude
.... 15.215 Altitude comparing intervention vs. comparator
.... 15.216 Altitude for enrolled group
.... 15.217 Altitude for screened group
.... 15.218 Altitude with comparator
.... 15.219 Altitude with intervention
.... 15.220 Analysis of formalin-fixed paraffin-embedded and blood and blood samples (NCT05327010)
.... 15.221 Analyzed Group in PARACHUTE Trial
.... 15.222 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 15.223 Anticoagulation for COVID-19 Combined RCTs PrePrint
.... 15.224 Assess emergent resistant mutations (NCT05327010)
.... 15.225 Baseline Characteristics Report for NCT03421379
.... 15.226 Baseline Characteristics Report for NCT03640312
.... 15.227 Baseline Characteristics Report for QUARTET Trial
.... 15.228 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.229 Baseline Measures List for PARACHUTE Trial
.... 15.230 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 15.231 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 15.232 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 15.233 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 15.234 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.235 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 15.236 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 15.237 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 15.238 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 15.239 BP-CONTROL Cardiovascular Outcomes Component: intensive versus standard blood-pressure control in adults at increased cardiovascular risk
.... 15.240 BP-CONTROL Master Protocol: blood-pressure targets in adults at increased cardiovascular risk
.... 15.241 Candesartan 8 mg once daily
.... 15.242 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.243 Change in Mean Diastolic Blood Pressure (NCT03640312)
.... 15.244 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.245 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.246 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.247 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 15.248 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 15.249 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312
.... 15.250 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.251 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.252 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.253 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.254 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.255 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.256 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.257 Citation for EBMonFHIR Implementation Guide
.... 15.258 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.259 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 15.260 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 15.261 Clinical benefit rate (CBR) (NCT05327010)
.... 15.262 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 15.263 Comparative Evidence Report Expanded for QUARTET USA Trial
.... 15.264 Comparative Evidence Report for QUARTET USA Trial
.... 15.265 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 15.266 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 15.267 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 15.268 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 15.269 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 15.270 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 15.271 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 15.272 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 15.273 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 15.274 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 15.275 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 15.276 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 15.277 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 15.278 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 15.279 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 15.280 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 15.281 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 15.282 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 15.283 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 15.284 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 15.285 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 15.286 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 15.287 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 15.288 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 15.289 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.290 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.291 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.292 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.293 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 15.294 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 15.295 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery
.... 15.296 ComparatorDefinition: Standard care
.... 15.297 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 15.298 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.299 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 15.300 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 15.301 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.302 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.303 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.304 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.305 Composite Rating of FOI 153881 for Project FOI 112280
.... 15.306 Computable_Publishing_LLC
.... 15.307 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 15.308 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.309 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.310 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.311 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.312 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 15.313 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 15.314 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 15.315 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 15.316 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 15.317 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 15.318 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 15.319 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 15.320 ConceptualCohortDefinition: Nonfatal stroke
.... 15.321 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter
.... 15.322 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter with Ranges
.... 15.323 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 15.324 ConceptualCohortDefinition: Severe obesity
.... 15.325 ConceptualCohortDefinition: T1DM or T2DM
.... 15.326 ConceptualCohortDefinition: T1DM-specific criteria
.... 15.327 ConceptualCohortDefinition: T2DM-specific criteria
.... 15.328 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 15.329 ConceptualCohortDefinition_Cardiovascular_event
.... 15.330 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.331 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 15.332 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.333 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 15.334 Correlate baseline mutations with treatment response (NCT05327010)
.... 15.335 Correlate changes in ctDNA variant allele frequencies with response (NCT05327010)
.... 15.336 Correlate mutation profiles with tumor sequencing (NCT05327010)
.... 15.337 Correlation of single nucleotide variant (SNV) and copy number variant (CNV) profiles with treatment response (NCT05327010)
.... 15.338 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 15.339 CTIS2024-516402-32-00 Eligibility Criteria
.... 15.340 CTIS2024-516402-32-00 Primary Outcome 1
.... 15.341 CTIS2024-516402-32-00 Secondary Outcome 1
.... 15.342 CTIS2024-516402-32-00 Secondary Outcome 2
.... 15.343 CTIS2024-516402-32-00 Secondary Outcome 3
.... 15.344 CTIS2024-516402-32-00 Secondary Outcome 4
.... 15.345 CTIS2024-516402-32-00 Secondary Outcome 5
.... 15.346 CTIS2024-516402-32-00 Secondary Outcome 6
.... 15.347 CTIS2024-516402-32-00 Secondary Outcome 7
.... 15.348 CTIS2024-516402-32-00 Secondary Outcome 8
.... 15.349 CTIS2025-523977-40-00 Eligibility Criteria - ARMYDA Study on Coronary Plaque Change with Semaglutide in Diabetes with ACS
.... 15.350 DatabaseCitation: Citation for FEvIR Platform
.... 15.351 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.352 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 15.353 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 15.354 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator
.... 15.355 Death or Major Traumatic Injury 30 days after Impact with comparator
.... 15.356 Death or Major Traumatic Injury 30 days after Impact with intervention
.... 15.357 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator
.... 15.358 declined randomization in PARACHUTE Study
.... 15.359 deemed unsuitable by investigator in PARACHUTE Trial
.... 15.360 Delany-Moretlwe 2022 clinical trial
.... 15.361 Diabetes treatment medication
.... 15.362 Diastolic blood pressure at 12 weeks
.... 15.363 DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure
.... 15.364 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days
.... 15.365 DichotomousIntendedOutcome: New onset depression
.... 15.366 DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke
.... 15.367 DichotomousIntendedOutcome: Remission of diabetes
.... 15.368 DichotomousIntendedOutcome: Treatment with opioids
.... 15.369 DIO: Mortality
.... 15.370 Duration of response (NCT05327010)
.... 15.371 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)
.... 15.372 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
.... 15.373 Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis
.... 15.374 Eligibility criteria for NMA_Diabetes
.... 15.375 Eligibility Criteria for QUARTET USA Trial
.... 15.376 Enrolled Group for QUARTET USA Trial
.... 15.377 Enrolled Group PARACHUTE Trial
.... 15.378 Ethnic Group
.... 15.379 Ethnic Group with comparator
.... 15.380 Ethnic Group with intervention
.... 15.381 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 15.382 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.383 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group
.... 15.384 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group
.... 15.385 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.386 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group
.... 15.387 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.388 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.389 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 15.390 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.391 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.392 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group
.... 15.393 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.394 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.395 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group
.... 15.396 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.397 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.398 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 15.399 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.400 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 15.401 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.402 EvidenceReportSectionCode Value Set
.... 15.403 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 15.404 EvidenceVariable Handling Extension Value Set
.... 15.405 EvidenceVariable: case_id
.... 15.406 EvidenceVariable: Patient id
.... 15.407 EvidenceVariable: Time of measurement
.... 15.408 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.409 Example of a ResearchStudySite
.... 15.410 Example of statistical model expression
.... 15.411 Excluded from PARACHUTE Study
.... 15.412 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 15.413 ExposureVariable: Age (as continuous variable)
.... 15.414 ExposureVariable: Body Mass Index (as continuous variable)
.... 15.415 Family History of Parachute Use
.... 15.416 Family History of Parachute Use with comparator
.... 15.417 Family History of Parachute Use with intervention
.... 15.418 Frequent Flier
.... 15.419 Frequent Flier with comparator
.... 15.420 Frequent Flier with intervention
.... 15.421 Gene expression profiling (NCT05327010)
.... 15.422 GLP-1 RA Group in Adults with type 2 diabetes
.... 15.423 GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.424 GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk
.... 15.425 Glucagon Hydrochloride Solution (Active Comparator)
.... 15.426 Glucagon Nasal Powder (Experimental)
.... 15.427 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial
.... 15.428 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial
.... 15.429 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 15.430 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.431 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 15.432 GroupAssignment: GLP-1 RA vs. Standard care
.... 15.433 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 15.434 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack
.... 15.435 GroupAssignment: Non Participants vs. Enrolled Participants
.... 15.436 GroupAssignment: Quadpill vs. Candesartan
.... 15.437 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 15.438 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 15.439 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 15.440 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 15.441 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 15.442 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 15.443 Health Survey Score Total
.... 15.444 Health Survey Score Total comparing intervention vs. comparator
.... 15.445 Health Survey Score Total with comparator
.... 15.446 Health Survey Score Total with intervention
.... 15.447 Health Survey Score-Mental Health Subscore
.... 15.448 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator
.... 15.449 Health Survey Score-Mental Health Subscore with comparator
.... 15.450 Health Survey Score-Mental Health Subscore with intervention
.... 15.451 Health Survey Score-Physical Health Subscore
.... 15.452 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator
.... 15.453 Health Survey Score-Physical Health Subscore with comparator
.... 15.454 Health Survey Score-Physical Health Subscore with intervention
.... 15.455 Health-related Quality of Life (NCT03640312)
.... 15.456 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
.... 15.457 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312
.... 15.458 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 15.459 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
.... 15.460 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312
.... 15.461 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 15.462 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.463 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.464 Height
.... 15.465 Height with comparator
.... 15.466 Height with intervention
.... 15.467 High Blood Pressure Medication Value Set
.... 15.468 History of Acrophobia
.... 15.469 History of Acrophobia with comparator
.... 15.470 History of Acrophobia with intervention
.... 15.471 History of Broken Bones
.... 15.472 History of Broken Bones with comparator
.... 15.473 History of Broken Bones with intervention
.... 15.474 History of Parachute Use
.... 15.475 History of Parachute Use with comparator
.... 15.476 History of Parachute Use with intervention
.... 15.477 Hypertension Control at 12 weeks
.... 15.478 ICD-10-GM Terminale Codes
.... 15.479 Incidence of adverse events (NCT05327010)
.... 15.480 Injury Severity Score 30 days after Impact comparing intervention vs. comparator
.... 15.481 Injury Severity Score 30 days after Impact with comparator
.... 15.482 Injury Severity Score 30 days after Impact with intervention
.... 15.483 Injury Severity Score on Impact comparing intervention vs. comparator
.... 15.484 Injury Severity Score on Impact with comparator
.... 15.485 Injury Severity Score on Impact with intervention
.... 15.486 International vs Domestic Flight
.... 15.487 International vs Domestic Flight with comparator
.... 15.488 International vs Domestic Flight with intervention
.... 15.489 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 15.490 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 15.491 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.492 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.493 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.494 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.495 Investigator
.... 15.496 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 15.497 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 15.498 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.499 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 15.500 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 15.501 Jumping from aircraft with empty backpack
.... 15.502 Jumping from aircraft with parachute
.... 15.503 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.504 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.505 M11 IGBJ Protocol Example Eligibility Criteria
.... 15.506 M11 Report for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.507 M11 Report for M11ResearchStudy Template
.... 15.508 M11 Report Section 1 (Protocol Summary) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.509 M11 Report Section 1 (Protocol Summary) for M11ResearchStudy Template
.... 15.510 M11 Report Section 10 (Statistical Considerations) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.511 M11 Report Section 10 (Statistical Considerations) for M11ResearchStudy Template
.... 15.512 M11 Report Section 11 (Trial Oversight) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.513 M11 Report Section 11 (Trial Oversight) for M11ResearchStudy Template
.... 15.514 M11 Report Section 12 (Supporting Details) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.515 M11 Report Section 12 (Supporting Details) for M11ResearchStudy Template
.... 15.516 M11 Report Section 13 (Glossary) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.517 M11 Report Section 13 (Glossary) for M11ResearchStudy Template
.... 15.518 M11 Report Section 14 (References) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.519 M11 Report Section 14 (References) for M11ResearchStudy Template
.... 15.520 M11 Report Section 2 (Introduction) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.521 M11 Report Section 2 (Introduction) for M11ResearchStudy Template
.... 15.522 M11 Report Section 3 (Trial Objectives and Associated Estimands) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.523 M11 Report Section 3 (Trial Objectives and Associated Estimands) for M11ResearchStudy Template
.... 15.524 M11 Report Section 4 (Trial Design) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.525 M11 Report Section 4 (Trial Design) for M11ResearchStudy Template
.... 15.526 M11 Report Section 5 (Trial Population) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.527 M11 Report Section 5 (Trial Population) for M11ResearchStudy Template
.... 15.528 M11 Report Section 6 (Trial Intervention) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.529 M11 Report Section 6 (Trial Intervention) for M11ResearchStudy Template
.... 15.530 M11 Report Section 7 (Participant Discontinuation) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.531 M11 Report Section 7 (Participant Discontinuation) for M11ResearchStudy Template
.... 15.532 M11 Report Section 8 (Trial Assessments) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.533 M11 Report Section 8 (Trial Assessments) for M11ResearchStudy Template
.... 15.534 M11 Report Section 9 (Adverse Events) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.535 M11 Report Section 9 (Adverse Events) for M11ResearchStudy Template
.... 15.536 M11ResearchStudy Template
.... 15.537 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.538 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.539 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.540 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.541 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.542 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.543 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.544 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.545 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.546 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.547 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.548 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.549 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.550 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.551 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.552 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.553 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.554 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.555 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.556 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.557 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.558 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.559 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.560 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.561 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.562 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.563 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.564 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.565 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.566 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.567 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.568 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.569 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.570 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.571 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.572 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.573 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.574 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.575 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.576 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.577 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.578 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.579 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.580 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.581 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.582 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.583 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.584 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.585 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.586 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.587 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.588 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.589 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.590 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.591 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.592 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.593 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.594 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.595 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.596 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.597 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.598 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.599 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.600 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.601 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.602 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.603 MAGICapp-derived Group: GLP-1 RA Group in Adults with type 2 diabetes
.... 15.604 Major adverse cardiovascular events (composite endpoint)
.... 15.605 Mean Change in Blood Urea Nitrogen (NCT03640312)
.... 15.606 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312
.... 15.607 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.608 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.609 Mean Change in Serum Creatinine (NCT03640312)
.... 15.610 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312
.... 15.611 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.612 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.613 Mean Change in Serum Potassium (NCT03640312)
.... 15.614 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
.... 15.615 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.616 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.617 Mean Change in Serum Sodium (NCT03640312)
.... 15.618 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312
.... 15.619 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.620 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.621 Mean Diastolic Blood Pressure (NCT03640312)
.... 15.622 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.623 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.624 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.625 Mean Systolic Blood Pressure (NCT03640312)
.... 15.626 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.627 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.628 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.629 Median Age of Parachute Intervention Group
.... 15.630 Medication Adherence (NCT03640312)
.... 15.631 Medication Adherence at 12 weeks
.... 15.632 Medication Adherence at 12 weeks for Candesartan in NCT03640312
.... 15.633 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.634 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.635 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 15.636 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 15.637 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 15.638 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.639 Mortality at 14 days
.... 15.640 NCT03421379 Eligibility Criteria
.... 15.641 NCT03640312 Eligibility Criteria
.... 15.642 NCT04401202 Eligibility Criteria
.... 15.643 NCT04401202_Enrollment_Group
.... 15.644 NCT05327010 Eligibility Criteria
.... 15.645 NetEffectContribution for ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 15.646 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 15.647 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 15.648 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 15.649 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 15.650 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 15.651 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 15.652 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 15.653 NetEffectEstimate for SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 15.654 NHANES LBDGLUSI Variable Definition Cohort Definition
.... 15.655 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 15.656 NHANES LBXGLU Variable Definition Cohort Definition
.... 15.657 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 15.658 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 15.659 NHANES SEQN Respondent Sequence Number
.... 15.660 NHANES WTSAF2YR Variable Definition Cohort Definition
.... 15.661 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 15.662 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 15.663 NT-proBNP Study Data Dictionary
.... 15.664 Number of Patients Requiring Step up Treatment (NCT03640312)
.... 15.665 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312
.... 15.666 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.667 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.668 Objective response rate (ORR) (NCT05327010)
.... 15.669 Organ support-free days
.... 15.670 Outcome Importance Rating 100 of All-cause mortality
.... 15.671 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 15.672 Outcome Importance Rating 5 of New onset depression
.... 15.673 Outcome Importance Rating 5 of Remission of diabetes
.... 15.674 Outcome Importance Rating 5 of Treatment with opioids
.... 15.675 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 15.676 Outcome Importance Rating of DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.677 Outcome Importance Rating of DichotomousIntendedOutcome: New onset depression for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.678 Outcome Importance Rating of DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.679 Outcome Importance Rating of DichotomousIntendedOutcome: Remission of diabetes for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.680 Outcome Importance Rating of DichotomousIntendedOutcome: Treatment with opioids for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.681 Outcome Importance Rating of Mortality for Bariatric Surgery Patients
.... 15.682 Outcome Measure List for QUARTET USA Trial
.... 15.683 Outcome Measure Report for QUARTET USA Trial
.... 15.684 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.685 Outcome Measures Report for NCT03421379
.... 15.686 Outcome Measures Report for NCT03640312
.... 15.687 Outcome Variables List for PARACHUTE Trial
.... 15.688 Outcome: Death or Major Traumatic Injury 30 days after Impact
.... 15.689 Outcome: Death or Major Traumatic Injury on Impact
.... 15.690 Outcome: Injury Severity Score 30 days after Impact
.... 15.691 Outcome: Injury Severity Score on Impact
.... 15.692 OutcomeDefinition for All-cause mortality
.... 15.693 OutcomeDefinition for Body weight
.... 15.694 OutcomeDefinition for Cardiovascular mortality
.... 15.695 OutcomeDefinition for End-stage kidney disease
.... 15.696 OutcomeDefinition for Health-related quality of life
.... 15.697 OutcomeDefinition for Heart failure
.... 15.698 OutcomeDefinition for Nonfatal myocardial infarction
.... 15.699 OutcomeDefinition for Nonfatal stroke
.... 15.700 OutcomeDefinition for Serious hyperglycaemia
.... 15.701 OutcomeDefinition for Severe gastrointestinal events
.... 15.702 OutcomeDefinition: Injury Severity Score on Impact
.... 15.703 OutcomeDefinition: All-cause mortality
.... 15.704 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 15.705 OutcomeDefinition: Body weight
.... 15.706 OutcomeDefinition: Cardiovascular mortality
.... 15.707 OutcomeDefinition: Diabetes in remission
.... 15.708 OutcomeDefinition: Diabetic ketoacidosis
.... 15.709 OutcomeDefinition: End-stage kidney disease
.... 15.710 OutcomeDefinition: Genital infection
.... 15.711 OutcomeDefinition: HbA1c at 12 months
.... 15.712 OutcomeDefinition: HbA1c at 24 months
.... 15.713 OutcomeDefinition: HbA1c at 36 months
.... 15.714 OutcomeDefinition: HbA1c at 6 months
.... 15.715 OutcomeDefinition: HbA1c at 60 months
.... 15.716 OutcomeDefinition: Health-related quality of life
.... 15.717 OutcomeDefinition: Heart failure
.... 15.718 OutcomeDefinition: Mortality at 14 days
.... 15.719 OutcomeDefinition: New onset depression
.... 15.720 OutcomeDefinition: Nonfatal myocardial infarction
.... 15.721 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 15.722 OutcomeDefinition: Nonfatal stroke
.... 15.723 OutcomeDefinition: Serious hyperglycaemia
.... 15.724 OutcomeDefinition: Severe gastrointestinal events
.... 15.725 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 15.726 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.727 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 15.728 OutcomeVariable: HbA1c at 12 months
.... 15.729 OutcomeVariable: HbA1c at 24 months
.... 15.730 OutcomeVariable: HbA1c at 36 months
.... 15.731 OutcomeVariable: HbA1c at 6 months
.... 15.732 OutcomeVariable: HbA1c at 60 months
.... 15.733 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 15.734 OutcomeVariable: New onset depression
.... 15.735 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 15.736 OutcomeVariable: Remission of diabetes
.... 15.737 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.738 OutcomeVariable_Additional_GI_surgical_procedure
.... 15.739 OutcomeVariable_All_cause_mortality
.... 15.740 OutcomeVariable_Treatment_with_opioids
.... 15.741 Overall survival (NCT05327010)
.... 15.742 PARACHUTE Trial baseline characteristics
.... 15.743 PARACHUTE Trial non participants
.... 15.744 PARACHUTE trial participant flow report
.... 15.745 PARACHUTE Trial Participants
.... 15.746 PARACHUTE Trial Participants assigned an empty backpack
.... 15.747 PARACHUTE trial participants assigned parachute
.... 15.748 PARACHUTE Trial Participants available for randomization
.... 15.749 PARACHUTE Trial Participants deemed unsuitable by investigator
.... 15.750 PARACHUTE Trial Participants randomized into groups
.... 15.751 PARACHUTE Trial Participants randomized into groups for screened group
.... 15.752 PARACHUTE Trial Participants randomized into groups with comparator
.... 15.753 PARACHUTE Trial Participants randomized into groups with intervention
.... 15.754 PARACHUTE Trial Participants that completed 30 day follow up
.... 15.755 PARACHUTE Trial Participants that completed 30 day follow up with comparator
.... 15.756 PARACHUTE Trial Participants that completed 30 day follow up with intervention
.... 15.757 PARACHUTE Trial Participants that completed jump and 5 minute follow-up
.... 15.758 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator
.... 15.759 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention
.... 15.760 PARACHUTE Trial Participants that declined randomization
.... 15.761 PARACHUTE Trial Participants with no contact at 30 days
.... 15.762 PARACHUTE Trial Participants with no contact at 30 days with comparator
.... 15.763 PARACHUTE Trial Participants with no contact at 30 days with intervention
.... 15.764 PARACHUTE Trial Results
.... 15.765 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 15.766 Parachute vs Empty Backpack in PARACHUTE Trial
.... 15.767 Participant Flow Report for NCT03421379
.... 15.768 Participant Flow Report for NCT03640312
.... 15.769 Participant Flow Report for QUARTET USA Trial
.... 15.770 Participant Flow Variables List for PARACHUTE Trial
.... 15.771 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 15.772 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 15.773 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 15.774 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 15.775 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 15.776 ParticipantFlowMeasure: Exclusion from analysis
.... 15.777 ParticipantFlowMeasure: Inclusion in analysis
.... 15.778 Participants Excluded from PARACHUTE Study
.... 15.779 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 15.780 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 15.781 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.782 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.783 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.784 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)
.... 15.785 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.786 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.787 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379
.... 15.788 Percentage of Participants With Clinical Recovery Within 14 Days After Randomization (NCT04401202)
.... 15.789 Percentage of Participants With Clinical Recovery Within 14 Days After Randomization - for Control in Nigella Sativa for COVID-19 OSF Preprint
.... 15.790 Percentage of Participants With Clinical Recovery Within 14 Days After Randomization - for Nigella Sativa Oil in Nigella Sativa for COVID-19 OSF Preprint
.... 15.791 Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint
.... 15.792 Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
.... 15.793 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312
.... 15.794 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.795 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.796 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
.... 15.797 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312
.... 15.798 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.799 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.800 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)
.... 15.801 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.802 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.803 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.804 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.805 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.806 PICO: Intensive versus standard blood-pressure control for major adverse cardiovascular events in adults at increased cardiovascular risk
.... 15.807 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.808 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.809 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.810 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.811 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.812 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.813 Placebo
.... 15.814 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.815 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.816 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 15.817 Progression-free survival (NCT05327010)
.... 15.818 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
.... 15.819 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312
.... 15.820 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.821 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.822 Proportion of Patients With Hypertension Control (NCT03640312)
.... 15.823 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
.... 15.824 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312
.... 15.825 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312
.... 15.826 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
.... 15.827 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312
.... 15.828 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312
.... 15.829 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.830 Quadpill once daily
.... 15.831 QUARTET USA Trial Control Group
.... 15.832 QUARTET USA Trial Quadpill group
.... 15.833 randomized into groups for PARACHUTE Trial
.... 15.834 Rate of Adverse Events of Special Interest (NCT03640312)
.... 15.835 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312
.... 15.836 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.837 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.838 Rate of Death or Major Traumatic Injury on Impact with comparator
.... 15.839 Rate of Death or Major Traumatic Injury on Impact with intervention
.... 15.840 Reasons for exclusion from QUARTET USA Trial
.... 15.841 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 15.842 Recommendation Justification Code System
.... 15.843 Recommendation Rating: ADA Obesity Management Recommendation 8.16
.... 15.844 Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.845 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 15.846 Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.847 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 15.848 Remdesivir
.... 15.849 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 15.850 ResearchStudy Classifier Code System
.... 15.851 Results Section for NCT03421379
.... 15.852 Results Section for NCT03640312
.... 15.853 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 15.854 Risk of Bias Assessment of PARACHUTE trial
.... 15.855 Risk Of Bias Type Value Set
.... 15.856 Screened Group PARACHUTE Trial
.... 15.857 Search Strategy for NMA_Diabetes
.... 15.858 SearchResults: PubMed search for Wonder Woman
.... 15.859 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 15.860 SearchStrategy: PubMed search for Wonder Woman
.... 15.861 Sex
.... 15.862 Sex with comparator
.... 15.863 Sex with intervention
.... 15.864 SGLT2 inhibitors Group in Adults with diabetes mellitus type 2
.... 15.865 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.866 SMR-excluded Tlayjeh H J Infect Public Health 33008778
.... 15.867 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 15.868 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 15.869 Spanish or English Value Set
.... 15.870 Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.871 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 15.872 StudyEligibilityCriteria for M11Report Example
.... 15.873 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 15.874 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 15.875 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 15.876 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 15.877 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 15.878 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 15.879 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 15.880 Summary of Findings - QUARTET USA Trial
.... 15.881 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 15.882 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.883 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.884 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 15.885 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.886 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.887 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.888 Systolic blood pressure at 12 weeks
.... 15.889 Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
.... 15.890 Time to integration of results in a recommendation
.... 15.891 Treatment-induced changes in phospho-protein signaling (NCT05327010)
.... 15.892 VariableDefinition: Comparator
.... 15.893 VariableDefinition: Condition(s)
.... 15.894 VariableDefinition: Date of birth
.... 15.895 VariableDefinition: Date of measurement
.... 15.896 VariableDefinition: Gender
.... 15.897 VariableDefinition: NTproBNP
.... 15.898 VariableDefinition: Unit
.... 15.899 Velocity
.... 15.900 Velocity comparing intervention vs. comparator
.... 15.901 Velocity for enrolled group
.... 15.902 Velocity for non participant group
.... 15.903 Velocity with comparator
.... 15.904 Velocity with intervention
.... 15.905 WebPageCitation: A HEvKA Update Summary
.... 15.906 Weight
.... 15.907 Weight with comparator
.... 15.908 Weight with intervention